Ricerc@Sapienza

Background: A new prepared oral viscous budesonide (PVB) has been effective in inducing clinical and histological remission in pediatric eosinophilic esophagitis (EoE). Aims: To evaluate the efficacy of a 12-week maintenance therapy on clinical, endoscopic, and histological remission using half of the dose used in the induction therapy. Methods: We prospectively enrolled pediatric patients with active EoE.

Topical steroids are effective in Eosinophilic Esophagitis (EoE), but
patients often show different tendencies to relapse. We assessed whether
gene expression is associated with a sort of "steroid dependency" in EoE
children.
Methods
Biopsy samples were prospectively collected on EoE children responding to
topical steroids. Patients treated with viscous budesonide for 24 weeks
were subsequently classified as early (6 months) or late (>6 months)
relapsing. RNA was isolated from esophageal biopsies at the time of the

Topical steroids are effective in Eosinophilic Esophagitis (EoE), but patients often show different tendencies to relapse. We assessed whether gene expression is associated with a sort of "steroid dependency" in EoE children. Methods: Biopsy samples were prospectively collected on EoE children responding to topical steroids. Patients treated with viscous budesonide for 24 weeks were subsequently classified as early (6 months) or late (>6 months) relapsing. RNA was isolated from esophageal biopsies at the time of the relapse and analyzed by NGS for transcriptome profiling.